Grace Therapeutics, Inc. (NASDAQ: GRCE) received official minutes from a Type A meeting with the U.S. Food and Drug Administration (FDA) on July 28, 2026, confirming that the regulator identified no clinical safety or efficacy deficiencies for its lead candidate, GTx-104. This development is critical for the late-stage biopharma company as it prepares to resubmit its New Drug Application (NDA) for the injectable formulation of nimodipine, developed for intravenous infusion to treat patients with aneurysmal subarachnoid hemorrhage (aSAH). The clarity from the FDA allows Grace Therapeutics to focus exclusively on resolving manufacturing compliance matters rather than conducting additional clinical trials.

The FDA meeting minutes serve as the official record of discussions regarding the Complete Response Letter (CRL) issued on April 23, 2026. As previously disclosed by the company, the CRL did not request any additional clinical data. Instead, the items cited by the FDA relate to current good manufacturing practice (cGMP) compliance status at the company's contract manufacturing organization. These are facility-level matters and do not represent product-specific quality findings for GTx-104. Additionally, the FDA requested additional leachables data time points and excipient toxicology risk assessments, which the company intends to address in its planned resubmission.

To mitigate supply chain risks and ensure timely resubmission, Grace Therapeutics is advancing a dual-source manufacturing strategy. The company’s current contract manufacturer is responsible for remediating the identified cGMP matters and demonstrating inspection readiness, a process that ultimately requires verification through an FDA reinspection. In parallel, the company is advancing technology transfer to a second-source contract manufacturer located in the United States. This approach provides more than one route to a compliant registration site and reduces reliance on any single manufacturing source.

Key Regulatory and Operational Details

The company has not designated a single path to resubmission; the NDA resubmission may be supported by either contract manufacturer or both. This flexibility is designed to accelerate the timeline toward regulatory approval while managing the complexities of the remediation process at the original facility.

What the Numbers Show

The separation of clinical success from manufacturing hurdles is a significant positive signal for investors. By confirming that GTx-104 has no clinical safety or efficacy deficiencies, the FDA has effectively validated the drug's therapeutic profile. The remaining obstacles are operational and regulatory compliance issues related to manufacturing, which are generally considered solvable through remediation and investment in quality systems, unlike clinical failures which require restarting trial phases. The dual-source strategy further de-risks the commercialization pathway by ensuring that a single facility's inspection delay does not block the entire program.

Grace Therapeutics, Inc. reported a net loss of $7.8 million, or $0.47 per share, for the fiscal year ended March 31, 2026, representing a decrease from a net loss of $9.6 million, or $0.79 per share, in the prior year. For the fourth quarter, the company reported a loss of $(0.06) per share, beating the analyst consensus estimate of $(0.15) by 60 percent. Management stated that existing cash and cash equivalents of $17.0 million are sufficient to sustain planned operations for at least 12 months.

Financial Performance

The reduction in the full-year net loss was driven by a substantial decrease in research and development expenses, which fell to $2.4 million from $9.5 million in the fiscal year ended March 31, 2025. The company attributed this $7.1 million decline primarily to the close-out of the GTx-104 pivotal Phase 3 safety clinical trial during the first calendar quarter of 2026. This decrease was partially offset by a $0.4 million increase in external consulting and data management costs related to the NDA submission.

General and administrative expenses rose to $8.7 million from $7.2 million in the prior year. The $1.5 million increase was largely due to $0.8 million in non-recurring legal and due diligence costs for strategic initiatives, alongside $0.9 million in professional fees for pre-commercial planning for GTx-104. These increases were partly mitigated by a $0.2 million reduction in salaries and benefits resulting from decreased headcount.

Regulatory and Business Updates

On April 23, 2026, the FDA issued a Complete Response Letter (CRL) for the GTx-104 NDA, referencing specific items in the Chemistry, Manufacturing, and Controls (CMC) and Non-Clinical sections. The company believes these items, which include additional leachable data time points, non-clinical product toxicology risk assessments, and current Good Manufacturing Practices (cGMP) deficiencies with a contract manufacturing organization, can be addressed in a resubmission. No clinical deficiencies were identified. A Type A meeting with the FDA has been scheduled to clarify the path forward.

During the fiscal year, the company presented Phase 3 STRIVE-ON trial results at several medical conferences, including the 2026 American Academy of Neurology and the Society of Critical Care Medicine's Critical Care Congress. Additionally, the U.S. Patent and Trademark Office issued U.S. Patent No. 12,414,943, covering the dosing regimen for IV administration of nimodipine used in the trial, extending intellectual property protection to 2043.

Consolidated Balance Sheet Data

Consolidated Statements of Loss Data